Cases of one of the world's deadliest diseases—tuberculosis—are rising at an alarming rate, despite widespread vaccination. Reasons for the ineffectiveness of the vaccine, especially in regions where this infectious disease is endemic, as well as arguments for replacing the existing vaccine with novel synthetic vaccines, are presented in a review published online August 28th in Trends in Molecular Medicine.

If you have trouble remembering whether you took your pills on time, your medicine may soon have the answer for you.

A strong partnership and shared strategy between employers, unions and surrounding communities was imperative in addressing the ravages caused by diseases such as HIV/Aids and tuberculosis (TB) in the workplace, said International Labour Organisation (ILO) senior technical advisor on health Simphiwe Mabhele.

Research to develop treatments for neglected tropical diseases received a boost this month as AstraZeneca concluded agreements through WIPO Re:Search with iThemba Pharmaceuticals (South Africa), the University of California, San Francisco (U.S), and the University of Dundee (UK). 

How the U.S.’s intellectual property demands for the Trans-Pacific Partnership Agreement threaten access to medicines.

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth’s C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.

Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI’s novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be conducted by Johnson County Clin-Trials in Lenexa, Kansas, in close collaboration with Aeras and IDRI.

AMES, Iowa – Edward Yu took note of the facts – nearly 2 million deaths each year, 9 million infected each year, developments of multidrug-resistant, extensively drug-resistant and now totally drug-resistant strains – and decided to shift his research focus to tuberculosis.

Project HOPE, a global health education and humanitarian assistance organization, has received $4.7 million from USAID to strengthen the tuberculosis (TB) infection control program in Ukraine.  The five-year program will be implemented with Chemonics.